ATE490774T1 - Verwendung von palonosetron zur behandlung von postoperativer übelkeit und erbrechen - Google Patents

Verwendung von palonosetron zur behandlung von postoperativer übelkeit und erbrechen

Info

Publication number
ATE490774T1
ATE490774T1 AT04712041T AT04712041T ATE490774T1 AT E490774 T1 ATE490774 T1 AT E490774T1 AT 04712041 T AT04712041 T AT 04712041T AT 04712041 T AT04712041 T AT 04712041T AT E490774 T1 ATE490774 T1 AT E490774T1
Authority
AT
Austria
Prior art keywords
vomiting
palonosetron
postoperative nausea
treat postoperative
treat
Prior art date
Application number
AT04712041T
Other languages
English (en)
Inventor
Luigi Baroni
Alberto Macciocchi
Enrico Braglia
Riccardo Braglia
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE490774(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Application granted granted Critical
Publication of ATE490774T1 publication Critical patent/ATE490774T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04712041T 2003-02-18 2004-02-18 Verwendung von palonosetron zur behandlung von postoperativer übelkeit und erbrechen ATE490774T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44834203P 2003-02-18 2003-02-18
PCT/EP2004/001558 WO2004073714A1 (en) 2003-02-18 2004-02-18 Use of palonosetron treating post-operative nausea and vomiting

Publications (1)

Publication Number Publication Date
ATE490774T1 true ATE490774T1 (de) 2010-12-15

Family

ID=32908576

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04712041T ATE490774T1 (de) 2003-02-18 2004-02-18 Verwendung von palonosetron zur behandlung von postoperativer übelkeit und erbrechen

Country Status (31)

Country Link
US (1) US20060074101A1 (de)
EP (2) EP2258367A3 (de)
JP (1) JP2006517944A (de)
KR (1) KR101113087B1 (de)
CN (1) CN1750822A (de)
AT (1) ATE490774T1 (de)
AU (1) AU2004212704B2 (de)
BR (1) BRPI0407549A (de)
CA (1) CA2515946C (de)
CU (1) CU23587B7 (de)
CY (1) CY1111312T1 (de)
DE (1) DE602004030424D1 (de)
DK (1) DK1596862T3 (de)
EA (1) EA013836B1 (de)
EC (1) ECSP055970A (de)
ES (1) ES2357769T3 (de)
GE (1) GEP20104908B (de)
HR (1) HRP20050709A2 (de)
IS (1) IS7983A (de)
MX (1) MXPA05008757A (de)
MY (1) MY143789A (de)
NO (1) NO20054296L (de)
NZ (1) NZ541862A (de)
PL (1) PL378122A1 (de)
PT (1) PT1596862E (de)
SI (1) SI1596862T1 (de)
TW (1) TWI355936B (de)
UA (1) UA96254C2 (de)
UY (1) UY28193A1 (de)
WO (1) WO2004073714A1 (de)
ZA (1) ZA200506580B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
KR20140088230A (ko) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
NZ570039A (en) * 2006-01-27 2011-07-29 Eurand Inc Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
CA2666512C (en) * 2006-10-24 2014-05-27 Helsinn Healthcare S.A. Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
US20090155363A1 (en) * 2007-12-14 2009-06-18 Todd Maibach Methods for oral administration of active drugs
WO2009139411A1 (ja) 2008-05-15 2009-11-19 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
WO2010077669A2 (en) * 2008-12-08 2010-07-08 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
ES2664599T3 (es) 2009-05-20 2018-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistas del receptor 5-HT3 de serotonina para uso en el tratamiento de trastornos vestibulares lesionales
EP2253316B1 (de) * 2009-05-20 2013-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin-5-HT3-Rezeptorantagonisten zur Verwendung bei der Behandlung oder Prävention einer Innenohr-Pathologie mit Vestibularisdefiziten
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
WO2011058427A1 (en) 2009-11-13 2011-05-19 Helsinn Healthcare S.A. Palonosetron metabolites
EP2722045B1 (de) 2009-11-18 2016-07-06 Helsinn Healthcare SA Zusammensetzungen zur Behandlung von zentral vermitteltem Unwohlsein und Erbrechen
CN106512010A (zh) 2009-11-18 2017-03-22 赫尔辛医疗股份公司 用于治疗中枢介导的恶心及呕吐的组合物及方法
KR101368587B1 (ko) * 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
WO2014004126A1 (en) 2012-06-26 2014-01-03 Fleming C Andrew Treating postoperative nausea and vomiting
MX2016008369A (es) 2013-12-23 2016-12-15 Samyang Biopharmaceuticals Composicion farmaceutica que incluye palonosetron.
HRP20240453T1 (hr) 2016-04-14 2024-06-21 Sensorion (+)-azasetron za uporabu u liječenju poremećaja uha
JP6768404B2 (ja) * 2016-08-12 2020-10-14 武田テバファーマ株式会社 パロノセトロン又はその薬学的に許容される塩を含む医薬組成物
JP6705348B2 (ja) * 2016-09-23 2020-06-03 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
KR101802183B1 (ko) * 2016-11-16 2017-11-28 주식회사 유영제약 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
FI3737378T3 (fi) * 2018-01-12 2023-06-02 Orion Corp Palonosetronisilmätipat pahoinvoinnin ja oksentelun hoitoon tai ehkäisyyn
CN108703960A (zh) * 2018-07-25 2018-10-26 无锡鑫连鑫生物医药科技有限公司 一种帕洛诺司琼缓释微球及其制备方法和使用方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
DE3650772T2 (de) 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
US5240954A (en) 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
GB8516083D0 (en) 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5578628A (en) 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4906755A (en) 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US4707484A (en) 1986-11-25 1987-11-17 Hoffmann-La Roche Inc. Substituted piperidinomethylindolone and cyclopent(b)indolone derivatives
US5011846A (en) 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
NZ236225A (en) 1989-11-28 1992-09-25 Syntex Inc Azabicyclic-substituted isoquinoline derivatives, intermediates and pharmaceutical compositions
US5189041A (en) 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
US5137893A (en) 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5491148A (en) 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9305593D0 (en) 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US5492914A (en) 1994-07-28 1996-02-20 Syntex (U.S.A.) Inc. 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US6294548B1 (en) 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
AU4551499A (en) * 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-HT3 receptors
AU753462B2 (en) * 1998-10-27 2002-10-17 Alcon Laboratories, Inc. Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
US6196963B1 (en) * 1999-03-02 2001-03-06 Medtronic Ave, Inc. Brachytherapy device assembly and method of use
AU2003237657A1 (en) * 2002-05-24 2003-12-12 Epidauros Biotechnologie Ag Means and methods for improved treatment using "setrones"
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
US8598219B2 (en) * 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron

Also Published As

Publication number Publication date
UY28193A1 (es) 2004-09-30
NZ541862A (en) 2008-04-30
CA2515946C (en) 2008-12-02
NO20054296D0 (no) 2005-09-16
EA200501318A1 (ru) 2006-02-24
PL378122A1 (pl) 2006-03-06
AU2004212704A1 (en) 2004-09-02
HRP20050709A2 (en) 2005-12-31
NO20054296L (no) 2005-11-17
GEP20104908B (en) 2010-03-10
EP2258367A2 (de) 2010-12-08
KR101113087B1 (ko) 2012-02-15
IS7983A (is) 2005-08-15
DE602004030424D1 (de) 2011-01-20
CA2515946A1 (en) 2004-09-02
PT1596862E (pt) 2011-03-15
ES2357769T3 (es) 2011-04-29
BRPI0407549A (pt) 2006-02-14
ZA200506580B (en) 2006-06-28
EP2258367A3 (de) 2011-07-13
EP1596862B1 (de) 2010-12-08
MY143789A (en) 2011-07-15
ECSP055970A (es) 2006-01-16
US20060074101A1 (en) 2006-04-06
TW200418474A (en) 2004-10-01
EP1596862A1 (de) 2005-11-23
DK1596862T3 (da) 2011-03-28
SI1596862T1 (sl) 2011-03-31
AU2004212704B2 (en) 2009-10-01
WO2004073714A1 (en) 2004-09-02
MXPA05008757A (es) 2006-05-31
HK1076402A1 (en) 2006-01-20
TWI355936B (en) 2012-01-11
UA96254C2 (uk) 2011-10-25
EA013836B1 (ru) 2010-08-30
JP2006517944A (ja) 2006-08-03
CY1111312T1 (el) 2015-08-05
CU23587B7 (es) 2010-10-30
CN1750822A (zh) 2006-03-22
KR20050121671A (ko) 2005-12-27

Similar Documents

Publication Publication Date Title
DE602004030424D1 (de) Verwendung von palonosetron zur behandlung von postoperativer übelkeit und erbrechen
BR0314059A (pt) Compostos heterocìclicos
MXPA04002983A (es) Derivados de quinuclidina, procedimientos para prepararlos y sus usos como inhibidores del receptor muscar??nico m2 y/o m3.
UA89734C2 (en) ANTAGONISTS of muscarinic acetylcholine receptors
HRP20080377A2 (en) ACTIVIN ActRIIa ANTAGONISTS AND USES FOR PROMOTING BONE GROWTH
DE60335717D1 (de) Azabicyclo-octan und nonan derivate mit ddp-iv hemmender wirkung
WO2009155054A3 (en) 5-ht3 receptor modulators, methods of making, and use thereof
DE60305052D1 (de) Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden
ATE539768T1 (de) Kombinationen von metabotropische-glutamat- rezeptor-antagonisten und ihre verwendung zur behandlung von suchtstörungen
DE60321965D1 (de) Amidfunktionelle polymere, zusammensetzungen und verfahren
ATE446753T1 (de) Verwendung von substituierten 2-thio-3,5-dicyano- 4-phenyl-6-aminopyridinen bei der behandlung von übelkeit und erbrechen
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
WO2011008572A3 (en) 5-ht3 receptor modulators, methods of making, and use thereof
NO20060775L (no) Muskarine acetylkolinreseptorantagonister
WO2007018564A3 (en) Enhancement of b cell proliferation by il-15
BRPI0519292A2 (pt) compostos orgÂnicos
NO20060776L (no) Muskarine acetylkolinreseptorantagonister
MXPA04004477A (es) Antagonistas del neuropeptido neuroquinina-1(nk1).
WO2005019200A3 (en) Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof
MXPA02012244A (es) 1-aminoalquilciclohexanos como 5-ht3 y antagonistas de receptor nicotinico neuronal.
EA200700146A1 (ru) Кристаллизированный полиэтилентерефталат, содержащий кремний, и способ его получения
WO2005112624A3 (en) Method for improving plant growth
DE60319989D1 (de) Diazabicylononan - und decanderivate und ihre verwendung als opioid-rezeptorligande
PL1978959T3 (pl) Pochodne piperydyny i piperazyny
DE60311000D1 (de) Indolderivate und deren verwendung als 5-ht liganden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1596862

Country of ref document: EP